Feedback / Questions
Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
DS-8201: Regulatory submission in EU for HER2 positive breast cancer in Q1 FY 2020
(Daiichi Sankyo)
-
Feb 1, 2020 -
Regulatory submission in Japan for HER2 positive gastric cancer in Q1 FY 2020
European regulatory • Japanese regulatory
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005468/FY2019%20Q3%20Presentation%20Material.pdf
Feb 1, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious